Spoken Alpha
TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries manufactures and distributes generic medicines, biosimilar medicines, and innovative pharmaceuticals across the United States, Europe, and international markets.
TEVA PHARMACEUTICAL INDUSTRIES LTD is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $45.12B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TEVA.
$ curl https://api.spokenalpha.com/v1/companies/TEVAFAQ
Spoken Alpha indexes TEVA's earnings call transcripts at https://spokenalpha.com/companies/TEVA. Each call links to attributed speakers and parsed analyst Q&A. TEVA PHARMACEUTICAL INDUSTRIES LTD's own investor relations page is at https://ir.tevapharm.com/investors/default.aspx.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) held its most recent earnings call on 2026-04-29, covering fiscal Q1 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $0.70 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-28 | $0.64 | $0.05 | +100.0% | $4.14B | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $0.53 | $0.46 | +15.2% | $3.98B | — | — | EODHD |
| Q4 FY2025 | 2026-01-27 | $0.96 | $0.64 | +50.0% | $4.71B | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $0.75 | $0.66 | +13.6% | $4.48B | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $0.66 | $0.62 | +6.5% | $4.18B | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.52 | $0.46 | +13.0% | $3.89B | — | — | EODHD |
| Q4 FY2024 | 2025-01-28 | $0.71 | $0.70 | +1.4% | $4.23B | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.69 | $0.66 | +4.5% | $4.33B | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $0.61 | $0.55 | +10.9% | $4.16B | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $0.48 | $0.51 | -5.9% | $3.82B | — | — | EODHD |
| Q4 FY2023 | 2024-01-30 | $1.00 | $0.76 | +31.6% | $4.46B | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $0.60 | $0.61 | -1.6% | $3.85B | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $0.56 | $0.53 | +5.7% | $3.88B | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $0.40 | $0.55 | -27.3% | $3.66B | — | — | EODHD |
| Q4 FY2022 | 2023-02-07 | $0.71 | $0.71 | 0.0% | $3.88B | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $0.59 | $0.62 | -4.8% | $3.60B | — | — | EODHD |
| Q2 FY2022 | 2022-07-25 | $0.68 | $0.56 | +21.4% | $3.79B | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $0.55 | $0.55 | 0.0% | $3.66B | — | — | EODHD |
| Q4 FY2021 | 2022-02-08 | $0.77 | $0.73 | +5.5% | $4.10B | — | — | EODHD |
Source: EODHD. TEVA reported actuals as published; sparse fields render as —.